Core Viewpoint - BellRing Brands Inc. is under investigation for potential violations of federal securities laws and unlawful business practices, following a significant drop in stock price after revealing slowed sales growth expectations [1][2]. Group 1: Company Performance - During the second quarter earnings call on May 6, 2025, BellRing Brands disclosed that certain customers are optimizing their inventories, leading to a forecasted sales growth slowdown to "low-single-digits" for the third quarter [2]. - Following this announcement, BellRing Brands' stock price fell by nearly 19% [2]. Group 2: Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against BellRing Brands on behalf of its stockholders, focusing on possible violations of federal securities laws [1]. - The law firm is reaching out to long-term stockholders who may have suffered losses and is encouraging them to participate in the investigation [3].

Core Viewpoint - The Schall Law Firm is investigating Capricor Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information regarding its Biologics License Application for deramiocel, a treatment for Duchenne muscular dystrophy cardiomyopathy [1][2]. Group 1 - The investigation is centered on whether Capricor issued false or misleading statements or failed to disclose important information to investors [2]. - On May 5, 2025, Capricor announced that the FDA confirmed its intent to hold an advisory committee meeting regarding the Company's BLA for deramiocel [2].